TROP2-Targeted Therapeutics in Development to Treat Gastrointestinal Tumors

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Trophoblast cell surface antigen 2 (TROP2) is overexpressed in various cancers.
• Antibody-drug conjugates (ADCs) targeting TROP2 are approved for breast and lung cancers.
• TROP2 ADCs have unique toxicities and require specific supportive care.

Purpose of the Study:

• To review the current progress of TROP2-targeting therapies in gastrointestinal (GI) malignancies.
• To explore the future potential of TROP2-targeting agents in GI cancers.
• To highlight the importance of discovering novel targeted therapies for GI malignancies.

Main Methods:

• Literature review of preclinical and clinical studies on TROP2-targeting agents in GI cancers.
• Analysis of early phase data for TROP2-targeted therapies in colorectal and gastroesophageal cancers.
• Examination of ongoing and planned investigations for TROP2-targeting agents in various GI malignancies.

Main Results:

• Early phase data indicate TROP2-targeted therapies show activity in colorectal and gastroesophageal cancers.
• Multiple TROP2-targeting agents are in development for a wide range of malignancies, including GI cancers.
• Combination strategies involving TROP2-targeting agents are under investigation.

Conclusions:

• TROP2-targeting therapies represent a promising avenue for treating GI malignancies.
• Further research and clinical trials are crucial to establish the efficacy and safety of TROP2-targeted agents in GI cancers.
• The development of novel targeted therapies for GI cancers, including TROP2-targeting agents, is of critical importance due to high mortality rates.